Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
doi: 10.1016/s0140-6736(17)30069-7 2 WuJDXuXHZhuJDingBDuTXGaoGet al
Clinical-trial results provide useful reference points, but they are averagesnot guarantees
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
That matters because GLP-1-based therapies typically lead to much higher systemic exposure
US$ 24.10
US$ 25.08
US$ 27.81
